1
|
Kleynhans J, Ebenhan T, Cleeren F, Sathekge MM. Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy? Eur J Nucl Med Mol Imaging 2024; 51:1965-1980. [PMID: 38676735 PMCID: PMC11139742 DOI: 10.1007/s00259-024-06719-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2024] [Accepted: 04/15/2024] [Indexed: 04/29/2024]
Abstract
Preclinical studies are essential for effectively evaluating TAT radiopharmaceuticals. Given the current suboptimal supply chain of these radionuclides, animal studies must be refined to produce the most translatable TAT agents with the greatest clinical potential. Vector design is pivotal, emphasizing harmonious physical and biological characteristics among the vector, target, and radionuclide. The scarcity of alpha-emitting radionuclides remains a significant consideration. Actinium-225 and lead-212 appear as the most readily available radionuclides at this stage. Available animal models for researchers encompass xenografts, allografts, and PDX (patient-derived xenograft) models. Emerging strategies for imaging alpha-emitters are also briefly explored. Ultimately, preclinical research must address two critical aspects: (1) offering valuable insights into balancing safety and efficacy, and (2) providing guidance on the optimal dosing of the TAT agent.
Collapse
Affiliation(s)
- Janke Kleynhans
- Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, 3000, Belgium
| | - Thomas Ebenhan
- Department of Nuclear Medicine, University of Pretoria, and Steve Biko Academic Hospital, Pretoria, 0001, South Africa
- Department of Nuclear Medicine, Steve Biko Academic Hospital, Pretoria, 0001, South Africa
| | - Frederik Cleeren
- Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, 3000, Belgium
| | - Mike Machaba Sathekge
- Department of Nuclear Medicine, Steve Biko Academic Hospital, Pretoria, 0001, South Africa.
- Preclinical Imaging Facility, Nuclear Medicine Research Infrastructure, Pretoria, 0001, South Africa.
| |
Collapse
|
2
|
Bidkar AP, Zerefa L, Yadav S, VanBrocklin HF, Flavell RR. Actinium-225 targeted alpha particle therapy for prostate cancer. Theranostics 2024; 14:2969-2992. [PMID: 38773983 PMCID: PMC11103494 DOI: 10.7150/thno.96403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2024] [Accepted: 05/01/2024] [Indexed: 05/24/2024] Open
Abstract
Targeted alpha particle therapy (TAT) has emerged as a promising strategy for the treatment of prostate cancer (PCa). Actinium-225 (225Ac), a potent alpha-emitting radionuclide, may be incorporated into targeting vectors, causing robust and in some cases sustained antitumor responses. The development of radiolabeling techniques involving EDTA, DOTA, DOTPA, and Macropa chelators has laid the groundwork for advancements in this field. At the forefront of clinical trials with 225Ac in PCa are PSMA-targeted TAT agents, notably [225Ac]Ac-PSMA-617, [225Ac]Ac-PSMA-I&T and [225Ac]Ac-J591. Ongoing investigations spotlight [225Ac]Ac-hu11B6, [225Ac]Ac-YS5, and [225Ac]Ac-SibuDAB, targeting hK2, CD46, and PSMA, respectively. Despite these efforts, hurdles in 225Ac production, daughter redistribution, and a lack of suitable imaging techniques hinder the development of TAT. To address these challenges and additional advantages, researchers are exploring alpha-emitting isotopes including 227Th, 223Ra, 211At, 213Bi, 212Pb or 149Tb, providing viable alternatives for TAT.
Collapse
Affiliation(s)
- Anil P. Bidkar
- Department of Radiology and Biomedical Imaging, University of California San Francisco, CA-94107, USA
| | - Luann Zerefa
- Department of Radiology and Biomedical Imaging, University of California San Francisco, CA-94107, USA
| | - Surekha Yadav
- Department of Radiology and Biomedical Imaging, University of California San Francisco, CA-94107, USA
| | - Henry F. VanBrocklin
- Department of Radiology and Biomedical Imaging, University of California San Francisco, CA-94107, USA
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA-94107, USA
| | - Robert R. Flavell
- Department of Radiology and Biomedical Imaging, University of California San Francisco, CA-94107, USA
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA-94107, USA
- Department of Pharmaceutical Chemistry, University of California, San Francisco, CA-94107, USA
| |
Collapse
|
3
|
Lucaroni L, Oehler S, Georgiev T, Müller M, Bocci M, De Luca R, Favalli N, Neri D, Cazzamalli S, Prati L. DNA-encoded chemical libraries enable the discovery of potent PSMA-ligands with substantially reduced affinity towards the GCPIII anti-target. Chem Sci 2024; 15:6789-6799. [PMID: 38725500 PMCID: PMC11077555 DOI: 10.1039/d3sc06668a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2023] [Accepted: 03/17/2024] [Indexed: 05/12/2024] Open
Abstract
Prostate-specific membrane antigen (PSMA) is a tumor-associated protein that has been successfully targeted with small organic ligands and monoclonal antibodies. Pluvicto™ is a PSMA-targeted radioligand therapeutic (RLT) recently approved by the FDA for the treatment of metastatic castration-resistant prostate cancer (2022 FDA marketing authorization). Although a large Phase III clinical trial (VISION trial) demonstrated clinical benefits in patients treated with Pluvicto™, the therapeutic window of the drug is narrowed by its undesired accumulation in healthy organs. Glutamate carboxypeptidase III (GCPIII), an enzyme sharing 70% identity with PSMA, may be responsible for the off-target accumulation of PSMA-RLTs in salivary glands and kidneys. In this work, we designed and synthesized affinity and selectivity maturation DNA-encoded chemical libraries (ASM-DELs) comprising 18'284'658 compounds that were screened in parallel against PSMA and GCPIII with the aim to identify potent and selective PSMA ligands for tumor-targeting applications. Compound A70-B104 was isolated as the most potent and selective ligand (KD of 900 pM for PSMA, KD of 40 nM for GCPIII). 177Lu-A70-B104-DOTA, a radiolabeled derivative of compound A70-B104, presented selective accumulation in PSMA-positive cancer lesions (i.e., 7.4% ID g-1, 2 hour time point) after systemic administration in tumor-bearing mice. The results of autoradiography experiments showed that 177Lu-A70-B104-DOTA selectively binds to PSMA-positive cancer tissues, while negligible binding on human salivary glands was observed.
Collapse
Affiliation(s)
- Laura Lucaroni
- Philochem AG, R&D Department CH-8112 Otelfingen Switzerland +41 43 544 88 19
| | - Sebastian Oehler
- Philochem AG, R&D Department CH-8112 Otelfingen Switzerland +41 43 544 88 19
| | - Tony Georgiev
- Philochem AG, R&D Department CH-8112 Otelfingen Switzerland +41 43 544 88 19
| | - Marco Müller
- Philochem AG, R&D Department CH-8112 Otelfingen Switzerland +41 43 544 88 19
| | - Matilde Bocci
- Philochem AG, R&D Department CH-8112 Otelfingen Switzerland +41 43 544 88 19
| | - Roberto De Luca
- Philochem AG, R&D Department CH-8112 Otelfingen Switzerland +41 43 544 88 19
| | - Nicholas Favalli
- Philochem AG, R&D Department CH-8112 Otelfingen Switzerland +41 43 544 88 19
| | - Dario Neri
- Philochem AG, R&D Department CH-8112 Otelfingen Switzerland +41 43 544 88 19
- Swiss Federal Institute of Technology, Department of Chemistry and Applied Biosciences CH-8093 Zurich Switzerland
- Philogen S.p.A. 53100 Siena Italy +39 0577 178 16 59
| | - Samuele Cazzamalli
- Philochem AG, R&D Department CH-8112 Otelfingen Switzerland +41 43 544 88 19
| | - Luca Prati
- Philogen S.p.A. 53100 Siena Italy +39 0577 178 16 59
| |
Collapse
|
4
|
Sun YC, Shi WX, Kuo WC, Hsiang YR, Lo WL, Chen LC, Farn SS, Lin YF, Chen KT. Cyanopyridoimidazole/1,2-Aminothiol Click Reaction: A Novel Bioorthogonal Reaction for Synthesis of Radiotracers. Bioconjug Chem 2024; 35:107-114. [PMID: 38108270 DOI: 10.1021/acs.bioconjchem.3c00496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2023]
Abstract
We herein described the design and synthesis of the cyanopyridoimidazoles (CPIs) as new bioorthogonal click reagents toward 1,2-aminothiol groups. Kinetic and density functional theory-based studies of the synthetic compounds revealed that incorporating an electron-withdrawing substituent into the CPI scaffold lowers its lowest unoccupied molecular orbital energy, consequently increasing reactivity. Optimized CPI 8a showed rapid reactivity and high stability in physiological conditions and has been demonstrated to be suitable for various radiotracer synthetic methods. Based on the new bioorthogonal reaction, a [67Ga]Ga-labeled prostate-specific membrane antigen-targeted probe was successfully prepared for in vivo imaging of prostate cancer in an animal model.
Collapse
Affiliation(s)
- Yi-Chen Sun
- Department of Chemistry, National Dong Hwa University, Hualien 974301, Taiwan
| | - Wei-Xin Shi
- Department of Chemistry, National Dong Hwa University, Hualien 974301, Taiwan
| | - Wei-Chieh Kuo
- Department of Chemistry, National Dong Hwa University, Hualien 974301, Taiwan
| | - Yi-Rong Hsiang
- Department of Chemistry, National Dong Hwa University, Hualien 974301, Taiwan
| | - Wei-Lin Lo
- National Atomic Research Institute, Taoyuan 325207, Taiwan
| | | | | | - Ya-Fan Lin
- Department of Chemistry, National Dong Hwa University, Hualien 974301, Taiwan
| | - Kuo-Ting Chen
- Department of Chemistry, National Dong Hwa University, Hualien 974301, Taiwan
| |
Collapse
|
5
|
Echavidre W, Fagret D, Faraggi M, Picco V, Montemagno C. Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future. Cancers (Basel) 2023; 15:4839. [PMID: 37835533 PMCID: PMC10572076 DOI: 10.3390/cancers15194839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2023] [Revised: 09/14/2023] [Accepted: 09/18/2023] [Indexed: 10/15/2023] Open
Abstract
The theranostic approach in oncology holds significant importance in personalized medicine and stands as an exciting field of molecular medicine. Significant achievements have been made in this field in recent decades, particularly in treating neuroendocrine tumors using 177-Lu-radiolabeled somatostatin analogs and, more recently, in addressing prostate cancer through prostate-specific-membrane-antigen targeted radionuclide therapy. The promising clinical results obtained in these indications paved the way for the further development of this approach. With the continuous discovery of new molecular players in tumorigenesis, the development of novel radiopharmaceuticals, and the potential combination of theranostics agents with immunotherapy, nuclear medicine is poised for significant advancements. The strategy of theranostics in oncology can be categorized into (1) repurposing nuclear medicine agents for other indications, (2) improving existing radiopharmaceuticals, and (3) developing new theranostics agents for tumor-specific antigens. In this review, we provide an overview of theranostic development and shed light on its potential integration into combined treatment strategies.
Collapse
Affiliation(s)
- William Echavidre
- Biomedical Department, Centre Scientifique de Monaco, 98000 Monaco, Monaco; (W.E.); (V.P.)
| | - Daniel Fagret
- Laboratory of Bioclinical Radiopharmaceutics, Universite Grenoble Alpes, CHU Grenoble Alpes, Inserm, 38000 Grenoble, France;
| | - Marc Faraggi
- Nuclear Medicine Department, Centre Hospitalier Princesse Grace, 98000 Monaco, Monaco;
| | - Vincent Picco
- Biomedical Department, Centre Scientifique de Monaco, 98000 Monaco, Monaco; (W.E.); (V.P.)
| | - Christopher Montemagno
- Biomedical Department, Centre Scientifique de Monaco, 98000 Monaco, Monaco; (W.E.); (V.P.)
| |
Collapse
|
6
|
Alati S, Singh R, Pomper MG, Rowe SP, Banerjee SR. Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer. Semin Nucl Med 2023; 53:663-686. [PMID: 37468417 DOI: 10.1053/j.semnuclmed.2023.06.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2023] [Revised: 06/19/2023] [Accepted: 06/21/2023] [Indexed: 07/21/2023]
Abstract
Prostate cancer is a leading cause of cancer death in men worldwide. Among the various treatment options, radiopharmaceutical therapy has shown notable success in metastatic, castration-resistant disease. Radiopharmaceutical therapy is a systemic approach that delivers cytotoxic radiation doses precisely to the malignant tumors and/or tumor microenvironment. Therapeutic radiopharmaceuticals are composed of a therapeutic radionuclide and a high-affinity, tumor-targeting carrier molecule. Therapeutic radionuclides used in preclinical prostate cancer studies are primarily α-, β--, or Auger-electron-emitting radiometals or radiohalogens. Monoclonal antibodies, antibody-derived fragments, peptides, and small molecules are frequently used as tumor-targeting molecules. Over the years, several important membrane-associated proteases and receptors have been identified, validated, and subsequently used for preclinical radiotherapeutic development for prostate cancer. Prostate-specific membrane antigen (PSMA) is the most well-studied prostate cancer-associated protease in preclinical literature. PSMA-targeting radiotherapeutic agents are being investigated using high-affinity antibody- and small-molecule-based agents for safety and efficacy. Early generations of such agents were developed simply by replacing radionuclides of the imaging agents with therapeutic ones. Later, extensive structure-activity relationship studies were conducted to address the safety and efficacy issues obtained from initial patient data. Recent regulatory approval of the 177Lu-labeled low-molecular-weight agent, 177Lu-PSMA-617, is a significant accomplishment. Current preclinical experiments are focused on the structural modification of 177Lu-PSMA-617 and relevant investigational agents to increase tumor targeting and reduce off-target binding and toxicity in healthy organs. While lutetium-177 (177Lu) remains the most widely used radionuclide, radiolabeled analogs with iodine-131 (128I), yttrium-90 (89Y), copper-67 (67Cu), and terbium-161 (161Tb) have been evaluated as potential alternatives in recent years. In addition, agents carrying the α-particle-emitting radiohalogen, astatine-211 (211At), or radiometals, actinium-225 (225Ac), lead-212 (212Pb), radium-223 (223Ra), and thorium-227 (227Th), have been increasingly investigated in preclinical research. Besides PSMA-based radiotherapeutics, other prominent prostate cancer-related proteases, for example, human kallikrein peptidases (HK2 and HK3), have been explored using monoclonal-antibody-(mAb)-based targeting platforms. Several promising mAbs targeting receptors overexpressed on the different stages of prostate cancer have also been developed for radiopharmaceutical therapy, for example, Delta-like ligand 3 (DLL-3), CD46, and CUB domain-containing protein 1 (CDCP1). Progress is also being made using peptide-based targeting platforms for the gastrin-releasing peptide receptor (GRPR), a well-established membrane-associated receptor expressed in localized and metastatic prostate cancers. Furthermore, mechanism-driven combination therapies appear to be a burgeoning area in the context of preclinical prostate cancer radiotherapeutics. Here, we review the current developments related to the preclinical radiopharmaceutical therapy of prostate cancer. These are summarized in two major topics: (1) therapeutic radionuclides and (2) tumor-targeting approaches using monoclonal antibodies, small molecules, and peptides.
Collapse
Affiliation(s)
- Suresh Alati
- Russell H. Morgan Department of Radiology and Radiological Science, Baltimore, MD; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - Rajan Singh
- Russell H. Morgan Department of Radiology and Radiological Science, Baltimore, MD; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - Martin G Pomper
- Russell H. Morgan Department of Radiology and Radiological Science, Baltimore, MD; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - Steven P Rowe
- Russell H. Morgan Department of Radiology and Radiological Science, Baltimore, MD; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - Sangeeta Ray Banerjee
- Russell H. Morgan Department of Radiology and Radiological Science, Baltimore, MD; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.
| |
Collapse
|
7
|
Meier JP, Zhang HJ, Freifelder R, Bhuiyan M, Selman P, Mendez M, Kankanamalage PHA, Brossard T, Pusateri A, Tsai HM, Leoni L, Penano S, Ghosh K, Broder BA, Markiewicz E, Renne A, Stadler W, Weichselbaum R, Nolen J, Kao CM, Chitneni SK, Rotsch DA, Szmulewitz RZ, Chen CT. Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel Theranostics. Molecules 2023; 28:6041. [PMID: 37630292 PMCID: PMC10458970 DOI: 10.3390/molecules28166041] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2023] [Revised: 07/20/2023] [Accepted: 07/21/2023] [Indexed: 08/27/2023] Open
Abstract
In the field of nuclear medicine, the β+ -emitting 43Sc and β- -emitting 47Sc are promising candidates in cancer diagnosis and targeted radionuclide therapy (TRT) due to their favorable decay schema and shared pharmacokinetics as a true theranostic pair. Additionally, scandium is a group-3 transition metal (like 177Lu) and exhibits affinity for DOTA-based chelators, which have been studied in depth, making the barrier to implementation lower for 43/47Sc than for other proposed true theranostics. Before 43/47Sc can see widespread pre-clinical evaluation, however, an accessible production methodology must be established and each isotope's radiolabeling and animal imaging capabilities studied with a widely utilized tracer. As such, a simple means of converting an 18 MeV biomedical cyclotron to support solid targets and produce 43Sc via the 42Ca(d,n)43Sc reaction has been devised, exhibiting reasonable yields. The NatTi(γ,p)47Sc reaction is also investigated along with the successful implementation of chemical separation and purification methods for 43/47Sc. The conjugation of 43/47Sc with PSMA-617 at specific activities of up to 8.94 MBq/nmol and the subsequent imaging of LNCaP-ENZaR tumor xenografts in mouse models with both 43/47Sc-PSMA-617 are also presented.
Collapse
Affiliation(s)
- Jason P. Meier
- Department of Radiology, The University of Chicago, Chicago, IL 60637, USA; (J.P.M.); (H.J.Z.); (R.F.); (M.B.); (A.P.); (S.P.); (K.G.); (B.A.B.); (A.R.); (C.-M.K.); (S.K.C.)
| | - Hannah J. Zhang
- Department of Radiology, The University of Chicago, Chicago, IL 60637, USA; (J.P.M.); (H.J.Z.); (R.F.); (M.B.); (A.P.); (S.P.); (K.G.); (B.A.B.); (A.R.); (C.-M.K.); (S.K.C.)
- Integrated Small Animal Imaging Research Resource, Office of Shared Research Facilities, The University of Chicago, Chicago, IL 60637, USA; (H.-M.T.); (L.L.); (E.M.)
| | - Richard Freifelder
- Department of Radiology, The University of Chicago, Chicago, IL 60637, USA; (J.P.M.); (H.J.Z.); (R.F.); (M.B.); (A.P.); (S.P.); (K.G.); (B.A.B.); (A.R.); (C.-M.K.); (S.K.C.)
- Cyclotron Facility, The University of Chicago, Chicago, IL 60637, USA
- UChicago/Argonne Joint Radioisotope Initiative (JRI), Chicago, IL 60637, USA; (W.S.); (R.W.); (J.N.)
| | - Mohammed Bhuiyan
- Department of Radiology, The University of Chicago, Chicago, IL 60637, USA; (J.P.M.); (H.J.Z.); (R.F.); (M.B.); (A.P.); (S.P.); (K.G.); (B.A.B.); (A.R.); (C.-M.K.); (S.K.C.)
- Cyclotron Facility, The University of Chicago, Chicago, IL 60637, USA
| | - Phillip Selman
- Department of Medicine, The University of Chicago, Chicago, IL 60637, USA; (P.S.); (M.M.)
| | - Megan Mendez
- Department of Medicine, The University of Chicago, Chicago, IL 60637, USA; (P.S.); (M.M.)
| | - Pavithra H. A. Kankanamalage
- Physics Division, Argonne National Laboratory, Lemont, IL 60439, USA; (P.H.A.K.); (T.B.)
- Collider Accelerator Department, Brookhaven National Laboratory, Upton, NY 11973, USA
| | - Thomas Brossard
- Physics Division, Argonne National Laboratory, Lemont, IL 60439, USA; (P.H.A.K.); (T.B.)
| | - Antonino Pusateri
- Department of Radiology, The University of Chicago, Chicago, IL 60637, USA; (J.P.M.); (H.J.Z.); (R.F.); (M.B.); (A.P.); (S.P.); (K.G.); (B.A.B.); (A.R.); (C.-M.K.); (S.K.C.)
| | - Hsiu-Ming Tsai
- Integrated Small Animal Imaging Research Resource, Office of Shared Research Facilities, The University of Chicago, Chicago, IL 60637, USA; (H.-M.T.); (L.L.); (E.M.)
| | - Lara Leoni
- Integrated Small Animal Imaging Research Resource, Office of Shared Research Facilities, The University of Chicago, Chicago, IL 60637, USA; (H.-M.T.); (L.L.); (E.M.)
| | - Sagada Penano
- Department of Radiology, The University of Chicago, Chicago, IL 60637, USA; (J.P.M.); (H.J.Z.); (R.F.); (M.B.); (A.P.); (S.P.); (K.G.); (B.A.B.); (A.R.); (C.-M.K.); (S.K.C.)
| | - Kaustab Ghosh
- Department of Radiology, The University of Chicago, Chicago, IL 60637, USA; (J.P.M.); (H.J.Z.); (R.F.); (M.B.); (A.P.); (S.P.); (K.G.); (B.A.B.); (A.R.); (C.-M.K.); (S.K.C.)
- Cyclotron Facility, The University of Chicago, Chicago, IL 60637, USA
| | - Brittany A. Broder
- Department of Radiology, The University of Chicago, Chicago, IL 60637, USA; (J.P.M.); (H.J.Z.); (R.F.); (M.B.); (A.P.); (S.P.); (K.G.); (B.A.B.); (A.R.); (C.-M.K.); (S.K.C.)
- National Institute of Standards and Technology, Gaithersburg, MD 20899, USA
| | - Erica Markiewicz
- Integrated Small Animal Imaging Research Resource, Office of Shared Research Facilities, The University of Chicago, Chicago, IL 60637, USA; (H.-M.T.); (L.L.); (E.M.)
| | - Amy Renne
- Department of Radiology, The University of Chicago, Chicago, IL 60637, USA; (J.P.M.); (H.J.Z.); (R.F.); (M.B.); (A.P.); (S.P.); (K.G.); (B.A.B.); (A.R.); (C.-M.K.); (S.K.C.)
- Physics Division, Argonne National Laboratory, Lemont, IL 60439, USA; (P.H.A.K.); (T.B.)
| | - Walter Stadler
- UChicago/Argonne Joint Radioisotope Initiative (JRI), Chicago, IL 60637, USA; (W.S.); (R.W.); (J.N.)
- Department of Medicine, The University of Chicago, Chicago, IL 60637, USA; (P.S.); (M.M.)
| | - Ralph Weichselbaum
- UChicago/Argonne Joint Radioisotope Initiative (JRI), Chicago, IL 60637, USA; (W.S.); (R.W.); (J.N.)
- Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, IL 60637, USA
| | - Jerry Nolen
- UChicago/Argonne Joint Radioisotope Initiative (JRI), Chicago, IL 60637, USA; (W.S.); (R.W.); (J.N.)
- Physics Division, Argonne National Laboratory, Lemont, IL 60439, USA; (P.H.A.K.); (T.B.)
| | - Chien-Min Kao
- Department of Radiology, The University of Chicago, Chicago, IL 60637, USA; (J.P.M.); (H.J.Z.); (R.F.); (M.B.); (A.P.); (S.P.); (K.G.); (B.A.B.); (A.R.); (C.-M.K.); (S.K.C.)
- Integrated Small Animal Imaging Research Resource, Office of Shared Research Facilities, The University of Chicago, Chicago, IL 60637, USA; (H.-M.T.); (L.L.); (E.M.)
- UChicago/Argonne Joint Radioisotope Initiative (JRI), Chicago, IL 60637, USA; (W.S.); (R.W.); (J.N.)
| | - Satish K. Chitneni
- Department of Radiology, The University of Chicago, Chicago, IL 60637, USA; (J.P.M.); (H.J.Z.); (R.F.); (M.B.); (A.P.); (S.P.); (K.G.); (B.A.B.); (A.R.); (C.-M.K.); (S.K.C.)
| | - David A. Rotsch
- UChicago/Argonne Joint Radioisotope Initiative (JRI), Chicago, IL 60637, USA; (W.S.); (R.W.); (J.N.)
- Physics Division, Argonne National Laboratory, Lemont, IL 60439, USA; (P.H.A.K.); (T.B.)
- Medical Isotope Development Group, Oak Ridge National Laboratory, Oak Ridge, TN 37830, USA
| | - Russell Z. Szmulewitz
- UChicago/Argonne Joint Radioisotope Initiative (JRI), Chicago, IL 60637, USA; (W.S.); (R.W.); (J.N.)
- Department of Medicine, The University of Chicago, Chicago, IL 60637, USA; (P.S.); (M.M.)
| | - Chin-Tu Chen
- Department of Radiology, The University of Chicago, Chicago, IL 60637, USA; (J.P.M.); (H.J.Z.); (R.F.); (M.B.); (A.P.); (S.P.); (K.G.); (B.A.B.); (A.R.); (C.-M.K.); (S.K.C.)
- Integrated Small Animal Imaging Research Resource, Office of Shared Research Facilities, The University of Chicago, Chicago, IL 60637, USA; (H.-M.T.); (L.L.); (E.M.)
- Cyclotron Facility, The University of Chicago, Chicago, IL 60637, USA
- UChicago/Argonne Joint Radioisotope Initiative (JRI), Chicago, IL 60637, USA; (W.S.); (R.W.); (J.N.)
| |
Collapse
|
8
|
Cheng L, Yang T, Zhang J, Gao F, Yang L, Tao W. The Application of Radiolabeled Targeted Molecular Probes for the Diagnosis and Treatment of Prostate Cancer. Korean J Radiol 2023; 24:574-589. [PMID: 37271211 DOI: 10.3348/kjr.2022.1002] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Revised: 03/26/2023] [Accepted: 03/30/2023] [Indexed: 06/06/2023] Open
Abstract
Radiopharmaceuticals targeting prostate-specific membrane antigens (PSMA) are essential for the diagnosis, evaluation, and treatment of prostate cancer (PCa), particularly metastatic castration-resistant PCa, for which conventional treatment is ineffective. These molecular probes include [68Ga]PSMA, [18F]PSMA, [Al18F]PSMA, [99mTc]PSMA, and [89Zr]PSMA, which are widely used for diagnosis, and [177Lu]PSMA and [225Ac]PSMA, which are used for treatment. There are also new types of radiopharmaceuticals. Due to the differentiation and heterogeneity of tumor cells, a subtype of PCa with an extremely poor prognosis, referred to as neuroendocrine prostate cancer (NEPC), has emerged, and its diagnosis and treatment present great challenges. To improve the detection rate of NEPC and prolong patient survival, many researchers have investigated the use of relevant radiopharmaceuticals as targeted molecular probes for the detection and treatment of NEPC lesions, including DOTA-TOC and DOTA-TATE for somatostatin receptors, 4A06 for CUB domain-containing protein 1, and FDG. This review focused on the specific molecular targets and various radionuclides that have been developed for PCa in recent years, including those mentioned above and several others, and aimed to provide valuable up-to-date information and research ideas for future studies.
Collapse
Affiliation(s)
- Luyi Cheng
- Department of Nuclear Medicine, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China
| | - Tianshuo Yang
- Department of Nuclear Medicine, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China
| | - Jun Zhang
- Department of Nuclear Medicine, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, Jiangsu, China
| | - Feng Gao
- Key Laboratory for Experimental Teratology of the Ministry of Education and Center for Experimental Nuclear Medicine, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
| | - Lingyun Yang
- JYAMS PET Research and Development Limited, Nanjing, Jiangsu, China
| | - Weijing Tao
- Department of Nuclear Medicine, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China.
| |
Collapse
|
9
|
[ 225Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [ 225Ac]Ac-PSMA-617. Cancers (Basel) 2022; 14:cancers14225651. [PMID: 36428743 PMCID: PMC9688344 DOI: 10.3390/cancers14225651] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2022] [Revised: 11/11/2022] [Accepted: 11/14/2022] [Indexed: 11/19/2022] Open
Abstract
In the present study, SibuDAB, an albumin-binding PSMA ligand, was investigated in combination with actinium-225 and the data were compared with those of [225Ac]Ac-PSMA-617. In vitro, [225Ac]Ac-SibuDAB and [225Ac]Ac-PSMA-617 showed similar tumor cell uptake and PSMA-binding affinities as their 177Lu-labeled counterparts. The in vitro binding to serum albumin in mouse and human blood plasma, respectively, was 2.8-fold and 1.4-fold increased for [225Ac]Ac-SibuDAB as compared to [177Lu]Lu-SibuDAB. In vivo, this characteristic was reflected by the longer retention of [225Ac]Ac-SibuDAB in the blood than previously seen for [177Lu]Lu-SibuDAB. Similar to [225Ac]Ac-PSMA-617, [225Ac]Ac-SibuDAB was well tolerated at 30 kBq per mouse. Differences in blood cell counts were observed between treated mice and untreated controls, but no major variations were observed between values obtained for [225Ac]Ac-SibuDAB and [225Ac]Ac-PSMA-617. [225Ac]Ac-SibuDAB was considerably more effective to treat PSMA-positive tumor xenografts than [225Ac]Ac-PSMA-617. Only 5 kBq per mouse were sufficient to eradicate the tumors, whereas tumor regrowth was observed for mice treated with 5 kBq [225Ac]Ac-PSMA-617 and only one out of six mice survived until the end of the study. The enhanced therapeutic efficacy of [225Ac]Ac-SibuDAB as compared to that of [225Ac]Ac-PSMA-617 and reasonable safety data qualify this novel radioligand as a candidate for targeted α-therapy of prostate cancer.
Collapse
|